FOX04-DRI (Proxofim)

Also known as Proxofim

FOX04-DRI, also known as Proxofim, is a senolytic peptide that selectively kills zombie-like senescent cells—aged, dysfunctional cells that accumulate with time, causing inflammation, tissue stiffness, and organ decline. By disrupting FOXO4-p53 interactions, it forces these cells into apoptosis while sparing healthy ones, rejuvenating tissues at the biological age level.

Route

Subcutaneous injection

Dose range

2 mg

Frequency

Once per day (subcutaneous) during designated dosing days

Cycle length

2–6 weeks (intermittent dosing)

Not currently stocked by N1 Aminos. Browse what is in stock →

Overview

FOX04-DRI, also known as Proxofim, is a senolytic peptide that selectively kills zombie-like senescent cells—aged, dysfunctional cells that accumulate with time, causing inflammation, tissue stiffness, and organ decline. By disrupting FOXO4-p53 interactions, it forces these cells into apoptosis while sparing healthy ones, rejuvenating tissues at the biological age level. Animal research shows restored organ function, reduced frailty, and extended healthy lifespan through improved insulin signaling and oxidative stress resistance.

Benefits spotlight clearer skin, stronger kidneys and heart, better mobility, and reversed aging markers like fur graying or kidney damage. It clears senescent burden systemically, enhancing cell cycle regulation and apoptosis in damaged cells only. Studies confirm younger tissue profiles post-treatment, with implications for age-related diseases like frailty or fibrosis. Injected periodically, FOX04-DRI offers rejuvenation without broad toxicity. Ideal for longevity seekers combating cellular aging, it pioneers targeted senescence clearance for renewed vitality across organs.

Studied benefits

  • A "senolytic" peptide designed to induce apoptosis (cell death) in aging, senescent cells while leaving healthy cells intact
  • Preclinical studies show it can restore fur density, improve organ function, and enhance physical fitness in aged models

Reported side effects

  • No human clinical trials have been completed
  • Animal studies suggest it is well-tolerated, with only minor injection-site reactions reported

Protocol

Dosing Schedule (Subcutaneous)

Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.

FOX04-DRI (10mg)

Reconstitute with 3.0 mL bacteriostatic water (Final concentration: 3.33 mg/mL).

Selectively eliminate senescent cells to support tissue rejuvenation and restore healthy cellular function.

PhaseDaily Dose (mg)Draw at 3.33 mg/mLLog
Days 1, 3, 5 (Week 1)2 mg60 units (0.6 mL)+ Log
Days 1, 3, 5 (Week 2)2 mg60 units (0.6 mL)+ Log

Frequency

Once per day (subcutaneous) during designated dosing days.

Timing

Any consistent time; rotate injection sites.

Cycle length

2–6 weeks (intermittent dosing).

Unit calculator

Set your vial and water; the table above updates.

Open the full calculator →
Concentration

3.33 mg/mL

5 doses of 2 mg per vial

At the starting dose (2 mg × 7/week for a 2-week cycle) you would use about 28 mg, i.e. 3 × 10 mg vials. Higher phases use proportionally more.

Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.

Context

Lifestyle considerations

Maintain a nutrient-dense, balanced diet rich in fiber and antioxidants to support the body’s clearance of senescent "zombie" cells during the peptide protocol. Stay physically active with moderate exercise to help the body process and eliminate the cellular debris generated by the senolytic process. Ensure 7–9 hours of quality sleep to support the tissue remodeling and regenerative phase that follows the clearance of aging cells. Allow for adequate "off-weeks" between research cycles to ensure the body has sufficient time for recovery and to avoid over-taxing the natural mechanisms of cellular turnover.

Evidence

Research summaries

FOXO4-DRI Regulates Endothelial Cell Senescence via the P53 Pathway

Findings: Clears out old, zombie-like cells from blood vessels, improves blood flow and vessel flexibility, reduces risks of heart disease from aging.

As we get older, some cells in our blood vessels turn into "senescent" zombies—they don't die but stick around, causing stiffness and poor blood flow, like clogged pipes. FOXO4-DRI (also called Proxofim) is a special peptide that targets these troublemakers. In mouse studies with natural aging or forced aging, injecting it cleared out these bad cells from the aorta (big artery), making vessels softer and better at pumping blood. It works by blocking FOXO4 from grabbing onto P53—a key protein that decides if cells live or die. This lets P53 move out of the cell's control center and trigger cleanup (apoptosis) just in senescent cells, leaving healthy ones alone. For teens, think of it as a smart janitor that removes junk buildup in your body's plumbing, keeping energy high for sports and preventing early tiredness or cramps from poor circulation. No harm to young cells; super selective. This could mean fewer worries about family heart issues later, with vessels staying stretchy like new rubber bands.

Read the study ↗

FOXO4-DRI Induces Keloid Senescent Fibroblast Apoptosis by Regulating p53-pS15 Translocation

Findings: Shrinks overgrowth scars (keloids), calms endless inflammation in skin, promotes smooth healing without relapse.

Keloids are bumpy scars that keep growing like weeds because senescent skin cells (fibroblasts) won't quit and inflame everything. Proxofim shots made these cells self-destruct by shifting a marked P53 protein (pS15) from the nucleus to outside, killing only the old troublemakers. In keloid models, it cut the pro-inflammatory crowd and mesenchymal bullies, easing the scar microenvironment. Mice with induced keloids saw less aggression and recurrence risk. Imagine post-acne or cut scars flattening naturally—no itchy, raised blobs embarrassing you at the beach. For active kids, quicker clean heals mean back to biking without keloid worries from falls. Safe, as it skips healthy fibroblasts. Ties to broader anti-senescence power, hinting at wrinkle prevention too. Clinical potential huge for cosmetic fixes.

Read the study ↗

Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells from Human Chondrocytes

Findings: Protects joint cartilage from wear, eases arthritis pain, supports knee/hip health for sports longevity.

Joint cells (chondrocytes) age in labs, causing stiff knees like old sneakers. FOXO4-DRI zapped these senescent ones selectively in expanded human cells for transplants, boosting fresh growth without toxicity. It disrupts FOXO4-P53 bonds, pushing death signals in zombies only. For 9th graders with soccer strains or growing pains, this means joints stay cushy, less creak during PE, and dodge early runner's knee. Animal hints show better mobility; human cartilage implants could last longer. Precision cleanup = youthful bounce.

Read the study ↗

FOXO4-DRI Regulates Endothelial Cell Senescence via the P53 Pathway

Findings: Clears out old, damaged blood vessel cells to improve blood flow, reduces vascular stiffness, and supports healthier aging of arteries.

As we get older, the cells lining our blood vessels (endothelial cells) turn into "zombie" cells called senescent cells—they stop dividing but stick around, causing stiffness and poor blood flow, like clogged pipes in a house. FOXO4-DRI (also called Proxofim) is a special peptide that targets these zombies. In studies with aged mice and cells stressed by low oxygen, it blocked FOXO4 from grabbing onto P53 (a key cell cleanup protein), pushing P53 out of the nucleus to trigger self-destruction of the bad cells via BAX and caspase-3 signals. This cleared the junk, making arteries more flexible and better at pumping blood. Mice showed improved aortic function—no more hardening. For a teen, think of it as a deep clean for your body's plumbing, preventing early fatigue during sports or growth spurts when blood needs to flow strong. No harm to healthy cells; it's picky, like a smart vacuum that only grabs dust.

Read the study ↗

FOXO4-DRI Induces Keloid Senescent Fibroblast Apoptosis by Regulating P53 Translocation

Findings: Shrinks overgrowth scars (keloids), calms ongoing skin inflammation, and stops aggressive scar tissue from coming back.

Keloids are scars that grow wild like weeds after cuts or piercings, thanks to senescent

Read the study ↗
More references (4)

Identification

Chemistry

cas
2460055-10-9 (primary); FOXO4-DRI acetate: separate CAS number for salt form
formula
C₂₂₈H₃₈₈N₈₆O₆₄ (free base); C₂₅₀H₄₃₂N₈₆O₈₆ (acetate salt form)
molecular weight
5,358.05-5,358.06 g/mol (free base); 6,019 g/mol (acetate salt form)
sequence
D-Leu-D-Thr-D-Leu-D-Arg-D-Lys-D-Glu-D-Pro-D-Ala-D-Ser-D-Glu-D-Ile-D-Ala-D-Gln-D-Ser-D-Ile-D-Leu-D-Glu-D-Ala-D-Tyr-D-Ser-D-Gln-D-Asn-Gly-D-Trp-D-Ala-D-Asn-D-Arg-D-Arg-D-Ser-Gly-Gly-D-Lys-D-Arg-D-Pro-D-Pro-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-Gly (all D-amino acids except noted L positions)
source
Synthetic; rationally designed to mimic FOXO4 protein with D-retro-inverso modifications
biosynthesis
Non-ribosomal; chemically synthesized through peptide bond formation with reversed sequence and D-amino acid substitution
type
Linear peptide; characterized by reversed amino acid sequence and D-amino acid composition

Keep exploring

Related peptides

Educational use only. The protocols shown summarise published research and community practice for informational purposes. They are not medical advice, not a prescription, and not a recommendation to use any compound. Research peptides are generally not approved for human use. Consult a licensed clinician. Full disclaimer.
Ask the advisor